title: Tissue factor pathway inhibitor (TFPI) antigen plasma level in patients with interstitial lung disease before and after heparin administration.
abstract: The extrinsic pathway is probably the predominant pathway in initiating blood coagulation in inflammatory lung diseases. Tissue factor pathway inhibitor (TFPI) is a Kunitz-type protease inhibitor of factor VIIa/tissue factor in the presence of factor Xa. As it has been shown recently that TFPI plasma levels are increased under acute inflammatory conditions, we studied TFPI antigen plasma levels before and after injecting 20 IU/kg body weight of unfractionated heparin into 49 patients with different stages of sarcoidosis, into 9 with idiopathic pulmonary fibrosis, and into 15 normal controls. TFPI, before injecting heparin, was significantly increased in all sarcoidosis stages (stage I: 97.6 +/- 6.4 ng/mL; stage II: 116.2 +/- 11.9 ng/mL; stage III: 116.3 +/- 7.3 ng/mL) and in idiopathic pulmonary fibrosis (116.8 +/- 16.1 ng/mL), as compared to the control group (77.7 +/- 3.3 ng/mL). No correlation was found between the intensity of the activity of sarcoidosis, measured as BAL white cell count, and TFPI. Five minutes after heparin administration the rise in TFPI was lower, although not statistically significant, in all sarcoidosis stages than in controls. In contrast, idiopathic pulmonary fibrosis had a similar or even higher TFPI elevation than the control group. In sarcoidosis the elevated TFPI and the lower capacity by endothelial cells to release TFPI after heparin may represent a compensatory mechanism to prevent blood clotting and/or the endothelial cell dysfunction of the microvasculature in this condition. In contrast, the extensive mesenchymal cell proliferation present in idiopathic pulmonary fibrosis could explain our findings, as it has been shown that cultured human mesangial cells produce and release TFPI.
authors.affiliation: Institute of Medical Semeiotics, University of Padua Medical School, Italy.
authors.forename: G
authors.initials: G
authors.lastname: Cella
authors.forename: A
authors.initials: A
authors.lastname: Cipriani
authors.forename: A
authors.initials: A
authors.lastname: Tommasini
authors.forename: E
authors.initials: E
authors.lastname: Rampin
authors.forename: A
authors.initials: A
authors.lastname: Sbarai
authors.forename: R
authors.initials: R
authors.lastname: Rocconi
authors.forename: G
authors.initials: G
authors.lastname: Mazzaro
authors.forename: G
authors.initials: G
authors.lastname: Luzzatto
mesh_terms: D000328:Adult; D000925:Anticoagulants / Q000008:administration & dosage*; D005260:Female; D006493:Heparin / Q000008:administration & dosage*; D006801:Humans; D008074:Lipoproteins / Q000097:blood*; D008297:Male; D011658:Pulmonary Fibrosis / Q000097:blood* / Q000188:drug therapy; D017565:Sarcoidosis, Pulmonary / Q000097:blood* / Q000188:drug therapy
chemical_list: D000925:Anticoagulants; D008074:Lipoproteins; C051928:lipoprotein-associated coagulation inhibitor; D006493:Heparin